Practice Committee of the American Society for Reproductive Medicine. Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline[J]. Fertil Steril, 2024, 121(2):230-245.
Maxwell K N, Cholst I N, Rosenwaks Z. The incidence of both serious and minor complications in young women undergoing oocyte donation[J]. Fertil Steril, 2008, 90(6):2165-2171.
[4]
Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Hyperstimulation Syndrome(Green-top Guideline No.5) [EB/OL]. 2016. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_5_ohss.Pdf
Kurioka H, Takahashi K, Kita N, et al. Hemorrhagic ovarian cyst without peritoneal bleeding in a patient with ovarian hyperstimulation syndrome: case report[J]. Chin Med J (Engl), 2005, 118(18):1577-1581.
[7]
Stojnic J, Bila J, Tulic L, et al. Severe hemoperitoneum due to ovarian bleeding after transvaginal oocyte retrieval with surgical management: a retrospective analysis and comprehensive review of the literature[J]. Medicina (Kaunas), 2023, 59(2):307.
[8]
Soares S R, Gómez R, Simón C, et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome[J]. Hum Reprod Update, 2008, 14(4):321-333.
[9]
Comba C, Ugurlucan F G, Bastu E, et al. Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome [J]. Arch Gynecol Obstet, 2014, 289(1): 223-225.
Abramov Y, Fatum M, Abrahamov D, et al. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report[J]. Fertil Steril, 2001, 75(6):1228-1230.
[13]
Yu Y T, Liu J, Hu B, et al. Expert consensus on the use of human serum albumin in critically ill patients[J]. Chin Med J (Engl), 2021, 134(14):1639-1654.
2025, Vol. 36 
